Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug interaction study reveals how carbamazepine may alter orforglipron exposure

NCT ID NCT06370728

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study examines whether carbamazepine, a common medication, changes how the body absorbs and clears orforglipron. Healthy volunteers receive orforglipron alone and then with carbamazepine to compare drug levels in the blood. The goal is to understand if dose adjustments are needed when these drugs are taken together.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
orforglipron and carbamazepine
What this could lead to
If successful, this study could help determine whether orforglipron doses need adjustment when taken with carbamazepine.
What could go wrong
This is an early-phase drug interaction study in healthy volunteers, not a treatment trial. Results may not predict effects in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

  • ICON Early Phase Services

    San Antonio, Texas, 78209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.